Jessica Tieszen | Associate Director of Investor Relations |
Mark Johnson | Vice President of Investor Relations |
Steve Davis | Chief Executive Officer |
Brendan Teehan | Chief Operating Officer, Head of Commercial |
Doug Williamson | Head of Research & Development |
Mark Schneyer | Chief Financial Officer |
Kathie Bishop | Head of Rare Diseases and External Innovation |
Tessa Romero | JPM |
Charles Duncan | Cantor Fitzgerald |
Marc Goodman | Leerink |
Gregory Renza | RBC Capital Markets |
Tazeen Ahmad | BOA |
Sumant Kulkarni | Canaccord Genuity |
Jason Butler | JMP |
Yatin Suneja | Guggenheim |
Ami Fadia | Needham and Company |
Jay Olson | Oppenheimer |
Good day, ladies and gentlemen and welcome to ACADIA Pharmaceuticals’ Second Quarter 2023 Financial Results Conference Call. My name is [Jeda] and I'll be your coordinator for today. At this time, all participants are in a listen-only mode.
We will be facilitating a question-and-answer session towards the end of today's call. [Operator Instructions]